Quick Answer
Dogwood Therapeutics, Inc. reported Total Assets of $90.17 million for the year ending 2025.
- Dogwood Therapeutics, Inc. showed a decrease of -4.4% in Total Assets from 2024 to 2025.
- This data is from Dogwood Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $28.27 million | Q2 2021: $23.76 million | Q3 2021: $20.11 million | Q1 2022: $12.55 million | Q2 2022: $9.04 million | Q3 2022: $10.86 million | Q1 2023: $6.52 million | Q2 2023: $5.21 million | Q3 2023: $5.25 million | Q1 2024: $3.22 million | Q2 2024: $3.64 million | Q3 2024: $2.28 million | Q1 2025: $96.98 million | Q2 2025: $96.69 million | Q3 2025: $91.99 million.
- Over the full 6 years of available data (2020 to 2025), Dogwood Therapeutics, Inc.'s Total Assets has grown by 186.5%.
- Historical annual values: Fiscal year 2025: $90.17 million | Fiscal year 2024: $94.31 million | Fiscal year 2023: $4.17 million | Fiscal year 2022: $8.37 million | Fiscal year 2021: $15.78 million | Fiscal year 2020: $31.47 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: